Name: In Vivo Star Anti-Mouse CD8a Antibody
Brand: InnoCyto
SKU: 508001
Price: 160 USD
Availability: InStock

Shop Now Contact

In Vivo Star Anti-Mouse CD8a Antibody

InnoCyto Product Image

Cat #	Size	Price
508001	1 mg	$160
508002	5 mg	$400
508003	25 mg	$1100

Bulk/Custom

Product Details

Clone	YTS 169.4
Application	ELISA, WB, Flow cytometry, IHC, ICC, animal model study
Host Species	CHO cells
Reactivity	Mouse
Format	Liquid
Target Name	CD8, CD8 alpha, T8, Lyt2, Ly-2
Product Description	In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody
Isotype	Rat IgG2b Kappa
Antibody Type	Recombinant
Regulatory Status	RUO
Purity	>95% by reducing SDS-PAGE
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions	4ºC
Grade	In vivo
Recommended Usage	This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
RRID	AB_3739354
Research Areas	T cells, T cell Activation, Adaptive Immunity
See All Formats	Clone YTS 169.4

Background Information

CD8 is a cell surface glycoprotein that plays a critical role in cellular immunity. It is most commonly expressed on cytotoxic T lymphocytes (CD8⁺ T cells), although lower levels can also be found on subsets of natural killer (NK) cells and dendritic cells.

Structurally, CD8 exists either as a homodimer of two CD8α chains (CD8αα) or, more commonly on T cells, as a heterodimer composed of CD8α and CD8β chains (CD8αβ). Each chain contains an extracellular immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail that associates with intracellular signaling molecules. Functionally, CD8 acts as a co-receptor for the T cell receptor (TCR) during antigen recognition. Its primary ligand is major histocompatibility complex class I (MHC I), which is expressed on nearly all nucleated cells. During immune surveillance, the TCR recognizes peptide antigens presented by MHC I, while CD8 binds to a conserved region of the MHC I molecule. This interaction stabilizes the TCR-peptide-MHC complex and brings the Src-family kinase Lck into proximity with the TCR signaling machinery, thereby enhancing signal transduction and lowering the threshold for T cell activation. Once activated, CD8⁺ T cells differentiate into cytotoxic effector cells capable of directly killing infected or malignant cells. They mediate target cell death primarily through the release of perforin and granzymes, which induce apoptosis, as well as through engagement of death receptor pathways such as Fas-Fas ligand interactions. CD8⁺ T cells also secrete cytokines, including interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), which further shape immune responses and inhibit pathogen replication.

CD8⁺ T cells are essential for protection against viral infections and for immune surveillance against cancer. However, their dysregulation contributes to disease. Insufficient CD8⁺ T cell responses can result in chronic viral infections or tumor immune evasion, while excessive or misdirected activity can cause tissue damage and contribute to autoimmune diseases, such as type 1 diabetes and multiple sclerosis. In chronic infections and cancer, persistent antigen exposure can drive CD8⁺ T cell exhaustion, characterized by reduced effector function and sustained expression of inhibitory receptors.

In therapeutics, CD8⁺ T cells are central to modern immunotherapy. Cancer treatments such as immune checkpoint inhibitors aim to reinvigorate exhausted CD8⁺ T cells, while adoptive cell therapies, including CAR-T and TCR-engineered T cells, harness or enhance CD8⁺ cytotoxic activity. CD8⁺ T cell responses are also a key goal of antiviral vaccines, underscoring their importance in both disease control and therapeutic intervention.

Frequently Asked Questions

What are In Vivo Star Biofunctional Antibodies?

In Vivo Star antibodies are premium-grade monoclonal antibodies purified and formulated specifically for use in animal studies. Each lot is manufactured under stringent quality controls to ensure the low endotoxin levels, high purity, and functional activity required for reliable in vivo results.

How are these antibodies different from standard research antibodies (e.g., for Western blot or flow cytometry)?

Standard research antibodies are optimized for in vitro detection assays and may contain preservatives, carrier proteins (like BSA), or higher endotoxin levels unsuitable for injection. In Vivo Star antibodies are formulated in injectable-grade, azide-free, low-endotoxin buffers and validated for functional bioactivity in living systems rather than just antigen binding.

What endotoxin and purity specifications do these antibodies meet?

All In Vivo Star antibodies are tested and certified to meet low-endotoxin thresholds (typically <1 EU/mg, lot-dependent) using the LAL (Limulus Amebocyte Lysate) assay, and are purified to ≥95% purity by SEC-HPLC or SDS-PAGE. Exact specifications are provided on the Certificate of Analysis (CoA) for each lot.

Are these antibodies azide-free and carrier-free?

All In Vivo Star antibodies are formulated without sodium azide and without carrier proteins such as BSA or gelatin, since both can interfere with animal physiology or immune readouts during in vivo studies.

Do you provide isotype controls?

Matched isotype control antibodies (same host species, isotype, and formulation) are available upon request for most clones to support proper experimental controls.

How should In Vivo Star antibodies be stored and handled?

Store at 4°C for short-term use and avoid repeated freeze-thaw cycles, which can reduce bioactivity; aliquoting is recommended for long-term storage per the product-specific storage instructions on the Certificate of Analysis. Always confirm storage conditions and expiration on the CoA that accompanies each lot, as these can vary slightly by antibody.

Have a product or application question? Consult our FAQs or contact us.

Search Tips